Flubrotizolam Stats & Data
Fc1ccccc1C1=NCc2nnc(C)n2c2sc(Br)cc12VOZDBDBHBXLWCG-UHFFFAOYSA-NEffect Profile
Curated + 3 ReportsStrong anxiolysis and euphoria with moderate cognitive impairment, mild sedation
Tolerance & Pharmacokinetics
drugs.wikiNo tolerance chart. Our decay curves for these drugs were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.
How fast tolerance to these drugs fades after a break has not been measured well enough to draw, so don't count on a dose you used to take still being safe: after time off, start with a much smaller amount and don't use alone. Mixing sedatives with each other, with alcohol or with opioids sharply raises the risk of a fatal overdose. If you've been using regularly, don't stop suddenly: withdrawal from benzodiazepines, alcohol or GHB/GBL can cause seizures or delirium, so get medical help to cut down gradually.
Sources: FRANK: benzodiazepines · Alcohol and Drug Foundation: GHB · FDA 2020: benzodiazepine boxed warning · FDA 2019: gabapentinoids and breathing · NHS: alcohol use disorder
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 3 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 2 of 3
- Not Specified 1 of 3
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 3 experience reports (3 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 3 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 1
Adverse Effects 0
Harm Reduction
drugs.wiki• Identity and synonyms: Flubrotizolam is a thienotriazolodiazepine; synonyms reported in chemical databases include Flurotizolam and research code LS‑152,574. This helps avoid confusion with similarly named benzodiazepines when checking results or labels.
• Potency: Active doses are typically in the sub‑milligram range; inaccurate measurement greatly increases risks of amnesia, injury, and respiratory depression. Volumetric dosing is recommended for solutions or powders to achieve microgram‑level accuracy.
• Onset and duration: Oral onset can be delayed up to 45–60 minutes with peaks at 1–3 hours; this lag increases the risk of impatient redosing and subsequent blackout. Plan doses with the delayed onset in mind.
• Next‑day sedation: Numerous user reports describe marked next‑day impairment and sedation; avoid driving or hazardous tasks for at least 24 hours after significant dosing.
• Tolerance and dependence: Tolerance can escalate quickly with daily or binge use; spacing doses and avoiding consecutive‑day use lowers risk of rapid tolerance and severe withdrawal.
• Interactions: Combining with other CNS depressants (alcohol, opioids, GHB/GBL, barbiturates, Z‑drugs, gabapentinoids) can cause unpredictable synergy leading to loss of consciousness and life‑threatening respiratory depression. Avoid polydrug depressant use.
• Mislabeling/adulteration: RC “Xanax” or “FANAX” style bars and benzo solutions may contain unexpected actives or stimulant admixtures; use reputable drug‑checking services where available and do not assume branding reflects contents.
• Overdose management: Primary treatment is supportive airway and breathing management; flumazenil can precipitate seizures or acute withdrawal in benzodiazepine‑tolerant individuals or mixed overdoses and should only be used by clinicians under appropriate indications.
• Route of administration: Non‑oral routes (e.g., injection, inhalation) increase harm without proven benefit; sublingual/oral routes are preferred if one chooses to use.
• Memory effects: Anterograde amnesia and “false sobriety” are common; pre‑plan environment, remove hazards, and avoid important tasks or conflict‑prone situations when under the influence.
• Product variability: Different vendors and batches vary in concentration and excipients; start with very small test doses from a new batch, even if experienced.
• Legal status and availability can change; possession may carry legal risk. Always verify current local regulations before obtaining or transporting substances.
References
Cited references
- PubChem Compound Summary: Flubrotizolam (CID 3044878)
- Isomer Design (Isomer Design) entry for Flubrotizolam (names/structure)
- TripSit harm‑reduction portal (combo chart access)
- TripSit Drug combinations wiki (depressant synergies)
- TripSit Benzo Converter (general benzodiazepine dose equivalence cautions)
- NCBI Bookshelf: Flumazenil (StatPearls) – seizure risk in dependent/mixed overdoses
- NCBI Bookshelf: Detoxification and Substance Abuse Treatment – flumazenil cautions
- NCBI Bookshelf: Nursing text – post‑benzodiazepine impairment caution (24–48 h)
- Saferparty Zürich warning: falsified ‘Xanax’ tablets containing potent NPS benzos (context for mislabel risk)
- Reddit r/rcbenzos4: Flubrotizolam trip report (onset ~45–60 min; 5–6 h primary effects; strong amnesia at higher doses)
- Reddit r/researchchemicals: Flubrotizolam discussion (next‑day sedation; rapid tolerance reports)
- Reddit r/benzodiazepines: FANAX bar lab result showing flubrotizolam plus FMA admixture (polydrug adulteration risk)